Announcing a new article publication for BIO Integration journal. Bladder cancer (BLCA) is one of the most common malignancies and the second most frequent urogenital tract tumor.

From a meeting that celebrates basic research and being "first," a look at 3 data sets on therapies that would break new ...

EQS-News: Pentixapharm Holding AG / Key word (s): Conference/Scientific publication Pentixapharm to Present First-in-Class Glycan-Dependent CD24 Antibody GT-008 for Solid Tumors at AACR 2025 ...

Conference/Scientific publicationPentixapharm to Present First-in-Class Glycan-Dependent CD24 Antibody GT-008 for Solid Tumors at AACR 2025 25.04.2025 / 15:39 CET/CESTThe issuer is solely responsible ...

A joint research team has developed a modular protein adapter technology that enables the stable attachment of various ...

South Korea-based DAAN Biotherapeutics has entered a licensing agreement with GC Cell, granting the latter exclusive rights ...

If anti-GAD65 antibodies are lower than the high titer threshold peripherally but positive in the cerebrospinal fluid (CSF), the subject can be included. A prior documented high titer anti-GAD65 ...

Get Instant Summarized Text (Gist) A novel approach using CAR-M (Chimeric Antigen Receptor Macrophages) has been developed to address the limitations of CAR-T therapy in treating solid tumors. By ...

Addressing the accessibility and high costs of chimeric antibody receptor (CAR) T-cell and bispecific therapies is crucial for maximizing their impact in multiple myeloma (MM). Patients once ...

The new research, described in a new study published in the Proceedings of the National Academy of Sciences, focuses on two powerful antibodies, hu11E6 and hu1B7, which neutralise the PT in ...

NK cells complexed with bispecific antibody yield high response rates in patients with lymphoma. ScienceDaily . Retrieved April 24, 2025 from www.sciencedaily.com / releases / 2025 / 04 ...